116 related articles for article (PubMed ID: 25656881)
41. When more is worse in clinical research and clinical practice.
Tassinari D; Tombesi P; Sartori S
Am J Clin Oncol; 2010 Aug; 33(4):424. PubMed ID: 20689366
[No Abstract] [Full Text] [Related]
42. Gastrointestinal cancer: FOLFOXIRI-improving outcomes of metastatic colorectal cancer.
Errico A
Nat Rev Clin Oncol; 2014 Dec; 11(12):684. PubMed ID: 25384949
[No Abstract] [Full Text] [Related]
43. How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?
Lindsay CR; Roxburgh P; Graham J
Future Oncol; 2013 Jun; 9(6):825-9. PubMed ID: 23718303
[TBL] [Abstract][Full Text] [Related]
44. A meta analysis of cetuximab plus oxaliplatin based chemotherapy regimen for metastatic colorectal cancer.
Zhu YL; Lou J; Guo JY; Huang Z; Lv SW
Indian J Cancer; 2014 Mar; 51 Suppl 3():e113-6. PubMed ID: 25818736
[TBL] [Abstract][Full Text] [Related]
45. Introduction: Emerging therapies with epidermal growth factor receptor-targeted agents in colorectal cancer.
Chu E
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S60-1. PubMed ID: 16336750
[No Abstract] [Full Text] [Related]
46. Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.
Láng I; Köhne CH; Folprecht G; Rougier P; Curran D; Hitre E; Sartorius U; Griebsch I; Van Cutsem E
Eur J Cancer; 2013 Jan; 49(2):439-48. PubMed ID: 23116683
[TBL] [Abstract][Full Text] [Related]
47. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
48. [Colorectal cancer: irinotecan in combination with newer drugs].
Falcone A
Tumori; 2001; 87(6):A31-3. PubMed ID: 11995705
[No Abstract] [Full Text] [Related]
49. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY
Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808
[TBL] [Abstract][Full Text] [Related]
50. KRAS status predicts response to cetuximab for metastatic colorectal cancer.
McBride D
ONS Connect; 2008 Aug; 23(8):25. PubMed ID: 18767573
[No Abstract] [Full Text] [Related]
51. Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer.
Halama N; Herrmann C; Jaeger D; Herrmann T
Anticancer Res; 2008; 28(6B):4111-5. PubMed ID: 19192669
[TBL] [Abstract][Full Text] [Related]
52. FOLFIRI with cetuximab or bevacizumab: FIRE-3.
Price TJ; Townsend AR; Peeters M
Lancet Oncol; 2014 Dec; 15(13):e582-e583. PubMed ID: 25456374
[No Abstract] [Full Text] [Related]
53. FOLFIRI with cetuximab or bevacizumab: FIRE-3.
Pietrantonio F; Iacovelli R; Di Bartolomeo M; de Braud F
Lancet Oncol; 2014 Dec; 15(13):e581. PubMed ID: 25456372
[No Abstract] [Full Text] [Related]
54. Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?
Hurwitz HI; Lyman GH
J Clin Oncol; 2012 Feb; 30(6):580-1. PubMed ID: 22253468
[No Abstract] [Full Text] [Related]
55. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
56. Antiangiogenesis drug promising for metastatic colorectal cancer.
McCarthy M
Lancet; 2003 Jun; 361(9373):1959. PubMed ID: 12801743
[No Abstract] [Full Text] [Related]
57. [Utilizing synergism].
Krankenpfl J; 2005; 43(4-6):145. PubMed ID: 16171088
[No Abstract] [Full Text] [Related]
58. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
[TBL] [Abstract][Full Text] [Related]
59. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.
Scartozzi M; Mandolesi A; Giampieri R; Pierantoni C; Loupakis F; Zaniboni A; Galizia E; Giustini L; Silva RR; Bisonni R; Berardi R; Biagetti S; Menzo S; Falcone A; Bearzi I; Cascinu S
Int J Cancer; 2010 Oct; 127(8):1941-7. PubMed ID: 20099280
[TBL] [Abstract][Full Text] [Related]
60. FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply.
Heinemann V; Stintzing S
Lancet Oncol; 2014 Dec; 15(13):e583-e584. PubMed ID: 25456375
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
